Latest From Grifols SA
Analysts said Grifols is poised for profit margin growth after the US FDA approved its first 20% subcutaneous immunoglobulin, Xembify, for treating primary immunodeficiencies.
US FDA Looks For Advisory Panel's Blessing Of Development Pathway For Monoclonal Antibodies In Rabies PEP
Public Company Edition: Four more IPOs in the US bring the year's total to seven – all in February. Also, Agenus launched its digital security offering, MacroGenics leads recent follow-on offerings and four companies reveal new job cuts.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Hematology, Coagulation
- Medical Devices
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Grifols SA
- Senior Management
- Victor Grifols Deu, Co-CEO
- Contact Info
Phone: (34) 93-5712200
Avinguda de la Generalitat, 152
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.